Patient info Open main menu

HELIOS INJURY 30C PILLULES - summary of medicine characteristics

Dostupné balení:

Summary of medicine characteristics - HELIOS INJURY 30C PILLULES

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Helios Injury 30c Pillules

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each pillule contains Arnica Montana 30c

Rhus toxicodendron (Toxicodendron quercifolium) 30c

Ruta Graveolans 30c

Also contains sucrose

For excipients, see section 6.1

3 PHARMACEUTICAL FORM

Pillules

White, hard, roughly spherical, approximately 4mm in diameter.

CLINICAL PARTICULARS

4.1 Therapeutic indications

A homeopathic medicinal product used within the homeopathic tradition for the symptomatic relief of pains and minor trauma associated with minor injuries,bruises, strains, sprains as well as minor emotional trauma associated with the above.

4.2 Posology and method of administration

For oral use only

Adults, the elderly and children 2 years and above: One pillule to be sucked as required for a maximum of three times daily.

Children under 2 years: One pillule to be given as required for a maximum of 3 times daily.

For children under 2 years old and consumers having difficulty sucking the pillule, it may be crushed or dissolved in half a teaspoonful of previously boiled, cooled water and then administered.

Do not take within 15 minutes of eating or drinking.

If symptoms worsen or do not improve after taking the product for 4 days, a doctor or qualified healthcare practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to Arnica montana , Rhus toxicodendron (Toxicodendron quercifolium)and Ruta graveolans preparations, other members of the Asteraceae (compositae ) family or to any of the excipients.

4.4 Special warnings and precautions for use

Do not exceed the stated dose

Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose/galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

If symptoms worsen or do not improve after 4 days of taking the product or if adverse events occur, a doctor or qualified healthcare practitioner should be consulted

4.5 Interaction with other medicinal products and other forms of interaction None known.

4.6 Fertility, pregnancy and lactation

Pregnancy: There is no evidence of the safety of the product in human pregnancy, nor is there any evidence from animal studies. Although no adverse events have been observed, the use of this product during pregnancy should be avoided unless under the guidance of a doctor.

Lactation: There is no evidence to suggest that the product should not be used during lactation.

Studies on fertility have not been performed

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

There are no known adverse effects.

If adverse effects occur a doctor or a qualified healthcare practitioner should be consulted.

4.9 Overdose

4.9 Overdose

None known

PHARMACOLOGICAL PROPERTIESPHARMACOLOGICAL PROPERTIES

5.1

5.2

Pharmacodynamic properties

Pharmacotherapeutic Group

The ATC code is V03. All other therapeutic groups.

Pharmacokinetic properties

Not applicable

5.3

Preclinical safety dataPreclinical safety data

Not applicable

PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose

6.2 Incompatibilities

None known

6.3 Shelf life

Five years

6.4 Special precautions for storage

Store below 30oC away from direct sunlight and strong odours.

6.5 Nature and contents of container

4g round plastic tubular dispenser consisting of a polypropylene body, polypropylene dispensing head and polystyrene cap. The main polypropylene body contains an inner polystyrene tube.

Pack size: 4g Pillules (100 approx)

6.6 Special precautions for disposal

6.6 Special precautions for disposal

There are no special storage precautions

7 MARKETING AUTHORISATION HOLDER

Helios Homeopathy Limited

89–97 Camden Road

Tunbridge Wells

Kent

TN1 2QR

U.K.

Tel 01892 537 254

Fax 01892 546850

Email johnm@helios.co­.uk

8 MARKETING AUTHORISATION NUMBER(S)

NR 27776/0001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

18/10/2012